Head-to-head evidence
Amivantamab vs Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline
Amivantamab
Marketed by Johnson & Johnson
NCT04965090 · Phase 2 · completed
This was a 43-person, single-arm, open-label study without randomization, blinding, or a comparator group. Its primary endpoints were CNS overall response rates measured by RECIST/RANO criteria, but results are not posted, so the primary endpoint outcome is unavailable.
Next expected readout: December 2026 · NCT06816992 (registry estimate)
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amivantamab's landscape · Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)'s landscape